Company profile
Cheplapharm Arzneimittel GmbH
acquired/legacy branded pharmaceuticals (specialty licensing and commercialization)
Privately held: no public share price · Greifswald, Germany
Assets
(6 total)
6Total Assets
6Approved
0Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Fluoropyrimidine (antimetabolite)Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Schizophrenia | |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Schizophrenia | |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Schizophrenia | |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | Schizophrenia | |
Tretinoin(Vesanoid) | Approved | RARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APLSmall molecule | Acute Myeloid Leukemia |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.